Mycobacterium avium subspecies paratuberculosis bacterial targets (MAP targets)

Mycobacterium avium subspecies paratuberculosis (MAP) is a slow-growing, acid-fast bacterium primarily known for causing Johne's disease, a chronic and often fatal enteritis in ruminants [1]. In humans, MAP has been extensively studied for its potential role in the pathogenesis of Crohn's disease, where it is thought to trigger chronic inflammation in genetically susceptible individuals [2]. The bacterial targets within MAP encompass a variety of essential proteins and pathways, including those involved in cell wall biosynthesis, energy metabolism, and nucleic acid synthesis [3]. Therapeutic intervention typically involves a combination of antibiotics, such as macrolides and rifamycins, which target the 50S ribosomal subunit and RNA polymerase, respectively [4]. Because MAP is an intracellular pathogen that can penetrate host cells and persist in a dormant state within macrophages, effective drug targeting requires agents that can maintain activity over long treatment durations [5]. Identifying specific, high-affinity targets within the MAP genome remains a critical area of research for developing more effective and selective anti-mycobacterial therapies [6].

Other names

MAP proteinsJohne's disease bacterial targetsMycobacterium avium paratuberculosis proteome

Inhibition of DNA-directed RNA polymerase, inhibition of protein synthesis via the 50S and 30S ribosomal subunits, and disruption of cell wall biosynthesis and membrane integrity.